Immunohistochemical Expression of CD8, CDX2, P53, D2-40 and KI 67 in Colorectal Adenocarcinoma, Conventional and Malignant Colo-rectal Polyps

2018 ◽  
Vol 69 (2) ◽  
pp. 419-428
Author(s):  
Cristian Mesina ◽  
Liviu Catalin Stoean ◽  
Ruxandra Stoean ◽  
Victor Adrian Sandita ◽  
Corina Lavinia Gruia ◽  
...  
Keyword(s):  
Lymph Node ◽  
Colorectal Adenocarcinoma ◽  
Rectal Adenocarcinoma ◽  
Distant Metastases ◽  
Lymphatic Invasion ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Rectal Polyps ◽  
Node Metastases ◽  
Lymph Nodes Metastases

82 patients, who had been diagnosed with colo-rectal adenocarcinoma in our department between 2007 and 2014, were included in our study. Additionally, 31 patients with colo-rectal polyps (20 conventional adenomatous polyps and 11 malignant colo-rectal polyps) were also included in this study. The patients with colo-rectal adenocarcinoma were reevaluated in terms of gender, age, topography of recto-colic tumor, TNM stadialization, vasculo-lymphatic invasion, lymph nodes metastases and distant metastases. The study of CD8, Ki67, p53, CDX2 and D2-40 immunoexpression in colo-rectal cancer patients revealed: an elevated positivity index in patients with pT2 and pT3 stages and in patients with lymph node metastases in case of the CD8; an elevated positivity index in patients with pT2, pT3 and pT4 stage in case of Ki67; an elevated positivity index in patients with pT4 stage in in case of the p53; an increased positivity index in the pT2, pT3 stage, the absence of vasculo-lymphatic invasion, the absence of lymph node and distant metastases in case of the CDX2 and an increased positivity index in patients with the pT2, pT3 stage, the abscence of lymph node and distant metastases in case of the D2-40 Tumoral staging (pT2, pT3 and pT4) has been shown to be correlated with immunoexpression of the following markers: CD8, CDX2 and p53.

Immunohistochemical expression of EGFR in colorectal adenocarcinoma and its correlation with the presence of lymph node metastases

2015 ◽  
Vol 87 (5) ◽  
pp. 364-367 ◽  
Author(s):  
G. Kapogiannatos ◽  
D. Margaritis ◽  
R. Alevizou ◽  
I. Gogoulou ◽  
A. Nomicos ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Colorectal Adenocarcinoma ◽  
Immunohistochemical Expression ◽  
Node Metastases

scholarly journals Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Kosei Takagi ◽  
Yuzo Umeda ◽  
Ryuichi Yoshida ◽  
Kazuhiro Yoshida ◽  
Kazuya Yasui ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumor ◽  
Lymph Node Metastases ◽  
Treatment Strategy ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Ki 67 ◽  
Invasive Approach ◽  
Robotic Pancreatoduodenectomy ◽  
Estimated Blood Loss ◽  
Node Metastases

Abstract Background Contrary to the increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), GEP-NETs of the accessory papilla of the duodenum are extremely rare. Furthermore, there have been no recommendations regarding the treatment strategy for GEP-NETs of the accessory papilla of the duodenum. We present a case of GEP-NET of the accessory papilla of the duodenum successfully treated with robotic pancreatoduodenectomy. Case presentation A case of a 70-year-old complaining of no symptoms was diagnosed with GEP-NET of the accessory papilla of the duodenum. A 8-mm tumor was located at the submucosal layer with a biopsy demonstrating a neuroendocrine tumor grade 1. The patient underwent robotic pancreatoduodenectomy as curative resection for the tumor. The total operative time was 406 min with an estimated blood loss of 150 mL. The histological examination revealed a well-differentiated neuroendocrine tumor with low Ki-67 index (< 1%). In the posterior areas of the pancreas, the lymph node metastases were detected. The patient was followed up for 6 months with no recurrence postoperatively. Conclusions Considering the potential risks of the lymph node metastases, the standard treatment strategy for GEP-NETs of the accessory papilla of the duodenum should be radical resection with pancreatoduodenectomy. Minimally invasive approach can be the alternative to the conventional open surgery.

scholarly journals Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors

2010 ◽  
Vol 47 (2) ◽  
pp. 141-147 ◽  
Author(s):  
Hunaldo Lima de Menezes ◽  
Mário Jorge Jucá ◽  
Edmundo Guilherme de A. Gomes ◽  
Benício L. Bulhões B. P. Nunes ◽  
Henrique Oliveira Costa ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cell Differentiation ◽  
Colorectal Adenocarcinoma ◽  
Sao Paulo ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Disease Free Interval ◽  
Free Interval ◽  
Specific Mortality ◽  
Disease Free

CONTEXT: Search of tumors markers that allow treatment with higher survival rates, and indicate the response to treatment and recurrence of cancer OBJECTIVE: To analyze the immunoexpression of the proteins p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and correlate them with the clinical-pathological prognostic factors. METHOD: Tissue microarray paraffin blocks were made from colorectal adenocarcinoma tissue resected from 82 patients who had undergone surgery but not chemotherapy or radiotherapy, at "Hospital São Paulo", São Paulo, SP, Brazil, between 2002 and 2005. Thin sections (4 µm) were subjected to immunohistochemical reactions, and immunoexpression staining scores were obtained. The scores were correlated with the degree of cell differentiation, staging, disease-free interval, recurrence, survival and specific mortality. The study variables were analyzed using the chi-square and Kaplan-Meier tests to investigate associations with the markers. The significance of the differences between the curves of the disease-free interval and survival was analyzed using the Logrank and Wilcoxon tests. RESULTS: The immunohistochemical expression of p53 was positive in 70 tumors (85.4%) and negative in 12 (14.6%). The expression of bcl-2 was positive in 26 (31.7%) and negative in 56 (68.3%). The expression of Ki-67 was positive in 62 (75.6%) and negative in 20 (24.4%). There was no statistically significant correlation between the expressions of these markers separately or in conjunction, in relation to the degree of cell differentiation, staging, disease-free interval, survival and specific mortality. In relation to recurrence, there was a statistically significant correlation with positive expression of Ki-67 (P = 0.035). CONCLUSION: The immunohistochemical expression of Ki-67 in colorectal cancer is associated with recurrence of this disease.

Immunohistochemical Expression of Ki-67 to Predict Lymph Node Involvement in Clinical Stage I Nonseminomatous Germ Cell Tumors

1997 ◽  
Vol 158 (2) ◽  
pp. 620-625 ◽  
Author(s):  
Axel Heidenreich ◽  
Noah S. Schenkmann ◽  
Isabell A. Sesterhenn ◽  
F. Kash Mostofi ◽  
William F. McCarthy ◽  
...  
Keyword(s):  
Lymph Node ◽  
Germ Cell ◽  
Clinical Stage ◽  
Germ Cell Tumors ◽  
Lymph Node Involvement ◽  
Stage I ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Node Involvement ◽  
Nonseminomatous Germ Cell Tumors

Multivariate analysis of prognostic factors among 706 mucosal melanoma patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9569-9569
Author(s):  
Bin Lian ◽  
Chuanliang Cui ◽  
Li Zhou ◽  
Xin Song ◽  
Xiaoshi Zhang ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Survival Rate ◽  
Lymph Node Metastases ◽  
Distant Metastases ◽  
Mucosal Melanoma ◽  
Depth Of Invasion ◽  
Prognostic Analysis ◽  
Node Metastases

9569 Background: Mucosal melanoma is rare and associated with extremely poor prognosis. Little is known about its outcome and prognostic analysis. In this study, we evaluated prognostic factors among mucosal melanomas. Methods: The survival rates, Relapse Free Survival (RFS), Overall Survival (OS) and prognostic factors were compared for 706 mucosal melanomas at different anatomical sites. Results: Mucosal melanoma from nasal pharyngeal and oral (268 pts), upper and lower gastrointestinal (GI) (221 pts), gynecological and urological (196 pts) had a similar survival with a 1-y survival rate (88%, 83%, 86%), 2-y survival rate (66%, 57%, 61%), 5-y survival rate (27%, 16%, 20%), respectively. Multivariate analysis revealed that Depth of Invasion (p < 0.001), Lymph node metastases (p < 0.001), Distant metastases (p < 0.001) were three independent prognostic factors for OS among 706 pts. Anatomical site (p = 0.031), Depth of Invasion (p < 0.001), Lymph node metastases (p < 0.001) were three independent prognostic factors for RFS among 543 pts. KPS status, Depth of Invasion, Lymph node metastases, Distant metastases were independent factors for OS among nasal pharyngeal and oral pts. Depth of Invasion, Lymph node metastases, CKIT Mutation were independent factors for RFS among nasal pharyngeal and oral pts. Gender, Lymph node metastases, Distant metastases were independent factors for OS among GI pts. Gender, Depth of Invasion, Lymph node metastases were independent factors for RFS among GI pts. Lymph node metastases, Distant metastases were independent factors for OS among Gynecological and Urological pts. Depth of Invasion, Lymph node metastases were independent factors for RFS among Gynecological and Urological pts. Conclusions: This is the first prognostic analysis for mucosal melanoma with the largest sample size for the first time. with few exceptions, It revealed that Depth of Invasion, Lymph node metastases, Distant metastases were independent prognostic factors for OS, Depth of Invasion and Lymph node metastases were independent prognostic factors for RFS. These results should be incorporated into the establishment of stage system and design of future clinical trials involving patients with mucosal melanoma.

Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk

2020 ◽  
Author(s):  
Giorgio Grani ◽  
Livia Lamartina ◽  
Marco AlfÒ ◽  
Valeria Ramundo ◽  
Rosa Falcone ◽  
...  
Keyword(s):  
Lymph Node ◽  
Soft Tissues ◽  
Distant Metastases ◽  
Central Compartment ◽  
Recurrence Risk ◽  
Lymph Node Status ◽  
Papillary Thyroid ◽  
Extrathyroidal Invasion ◽  
Node Metastases

Abstract Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for papillary thyroid cancer (PTC). Objective To determine how policy changes affect the use of RAI and the short-term outcomes of patients. Design Retrospective analysis of longitudinal data. Setting Academic referral center. Patients Patients with non-aggressive PTC variants; no extrathyroidal invasion or limited to soft tissues, no distant metastases, and ≤5 central-compartment cervical lymph node metastases. In Cohort 1, standard treatments were total thyroidectomy and RAI (May 2005-June 2011); in Cohort 2 decisions on RAI were deferred for ~12 months after surgery (July 2011-December 2018). Propensity score matching was used to adjust for sex, age, tumor size, lymph node status, and extrathyroidal extension. Intervention Immediate RAI or deferred choice. Main outcome measures Responses to initial treatment in ≥3 years of follow-up. Results In Cohort 1, RAI was performed in 50/116 patients (51.7%), while in Cohort 2, it was far less frequent: immediately in 10/156 (6.4%), and in 3 more patients after the first follow-up data. The frequencies of structural incomplete response were low (1-3%), and there were no differences between the two cohorts at any follow-up visit. Cohort 2 patients had higher rates of “gray-zone responses” (biochemical incomplete or indeterminate response). Conclusions Selective use of RAI increases the rate of patients with “uncertain” status during early follow-up. The rate of structural incomplete responses remains low regardless of whether RAI is used immediately or not. Patients should be made aware of both the advantages and drawbacks of omitting RAI.

scholarly journals ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy

2010 ◽  
Vol 1 (6) ◽  
pp. 1067-1071 ◽  
Author(s):  
LUIZA KANCZUGA-KODA ◽  
MARIUSZ KODA ◽  
JAKUB TOMASZEWSKI ◽  
KATARZYNA JARZABEK ◽  
JOANNA LOTOWSKA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Ki 67 ◽  
Primary Tumors ◽  
Node Metastases

Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer

2009 ◽  
Vol 48 (03) ◽  
pp. 89-98 ◽  
Author(s):  
M. K. Pixberg ◽  
B. Riemann ◽  
A. Schuck ◽  
A. Heinecke ◽  
K. W. Schmid ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Differentiated Thyroid Cancer ◽  
Regional Lymph Node ◽  
Statistical Significance ◽  
External Beam Radiotherapy ◽  
Distant Metastases ◽  
External Beam ◽  
Node Metastases

Summary Aim: Evaluate the clinical benefit of external beam radiotherapy (RTx) for locally invasive thyroid carcinoma with follicular cell differentiation (DTC). Patients, methods: The Multicentre Study on Differentiated Thyroid Cancer (MSDS) was planned as a prospective multicenter trial on the benefit of adjuvant RTx in locally invasive DTC (pT4; UICC 1997) with or without lymph node metastases and no known distant metastases. All patients were treated with thyroidectomy, 131I-therapy, and TSH-suppression and were randomized to receive additional RTx or not. In 4/2003 the trial became a prospective cohort study after only 45 of then 311 patients had consented to randomization. 351 of 422 patients met the trial's inclusion criteria. Age was 48 ± 12 years (mean ± SD). 25% were men. Tumours were papillary in 90% and follicular in 10%. Of 47 patients randomized or allocated to RTx, 26 actually received RTx. Results: Mean followup was 930 days. In an actual treatment analysis, 96% (25/26) of the RTx-patients reached complete remission (CR) vs. 86% in the non-RTx patients. Recurrences occurred in 0 vs. 3 % of patients: 6 reoperated for regional lymph node metastases, 1 tracheal invasion treated with tracheoplasty, 1 local invasion necessitating laryngectomy, 2 distant metastases (1 lung, 1 lung + bone). Serious chronic RTx toxicity occurred in 1/26 patients. Conclusion: The MSDS trial showed low mortality and recurrence rates and a weak benefit of RTx in terms of local control that did however not reach statistical significance. Routine RTx in locally invasive DTC can no longer be recommended .

Sign in / Sign up

Export Citation Format

Share Document